Quince Therapeutics, Inc.

QNCXCIK 0001662774 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K filed Apr 10, 2026. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0196

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

May 21, 2026no items parsed May 18, 2026no items parsed May 18, 2026no items parsed Apr 28, 2026no items parsed Apr 22, 20265.02 · Departure/Election

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Quince Therapeutics, Inc.

Name	Roles	Filings
Hannah Brendan	Officer	12
Lamond David	Director	12
Thye Dirk	OfficerDirector	12
McLoughlin Margaret	Director	7
Bray June	Director	6

Showing 1-5 of 21

Per pagePage 1 of 5Next

Top performers

Insiders ranked by realized 90-day signed return on their open-market trades at Quince Therapeutics, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.

#	Insider	Trades	Win rate	Avg	Median	Best	Worst
1	Hannah Brendan	6	100%	+181.7%	+181.7%	+186.9%	+176.6%

All filings

96 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jan 23, 2026	Hannah Brendan CBO, COO & CCO	Holdings only	-	-	-

Filed		Top transaction	Shares	Price	Value